How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,633 results for

Uterine Fibroid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Acupuncture for uterine fibroids: Protocol for a systematic review of randomized controlled trials. (PubMed)

Acupuncture for uterine fibroids: Protocol for a systematic review of randomized controlled trials. Uterine fibroids represent the most common gynecological benign tumors in reproductive females. Acupuncture has been applied as a therapeutic modality in China to treat uterine fibroids. However, currently, few critical systematic reviews regarding the effect of acupuncture on uterine fibroids have been published. Our proposed review aims to evaluate the current evidence on the efficacy (...) of acupuncture for uterine fibroids.A total of 7 databases were searched from their inception to December 2018, including PubMed, Medline, Embase, the Cochrane Central Register of Controlled Trials, the Chinese National Knowledge Infrastructure database, the Chinese Biomedical database, and the Wanfang database. The primary outcomes will be reduction in uterine volume and number of fibroids. Secondary outcomes are pelvic or low-back pain, assessed by Visual Analog Scale (VAS); Irregular menstrual periods

2019 Medicine

42. Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing

Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing | European Medicines Agency Search Search Menu Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing Press release 09/02/2018 No new patients should start treatment for the time being European Medicines Agency's (EMA) ( ) is currently reviewing the benefits (...) and risks with Esmya, following reports of serious liver injury, including liver failure leading to transplantation. As a temporary measure while the review is ongoing, the has recommended regular liver monitoring for women taking Esmya for uterine fibroids. All women taking Esmya should have a liver function test at least once a month during treatment. If the test is abnormal (liver enzyme levels more than 2 times the upper limit of normal), the healthcare professional should stop treatment and closely

2018 European Medicines Agency - EPARs

43. Implementation of the uterine fibroids Option Grid patient decision aids across five organizational settings: a randomized stepped-wedge study protocol. (PubMed)

Implementation of the uterine fibroids Option Grid patient decision aids across five organizational settings: a randomized stepped-wedge study protocol. Uterine fibroids are non-cancerous overgrowths of the smooth muscle in the uterus. As they grow, some cause problems such as heavy menstrual bleeding, pelvic pain, discomfort during sexual intercourse, and rarely pregnancy complications or difficulty becoming pregnant. Multiple treatment options are available. The lack of comparative evidence (...) demonstrating superiority of any one treatment means that choosing the best option is sensitive to individual preferences. Women with fibroids wish to consider treatment trade-offs. Tools known as patient decision aids (PDAs) are effective in increasing patient engagement in the decision-making process. However, the implementation of PDAs in routine care remains challenging. Our aim is to use a multi-component implementation strategy to implement the uterine fibroids Option Grid™ PDAs at five organizational

2019 Implementation Science Controlled trial quality: uncertain

44. Lower prevalence of non-cavity-distorting uterine fibroids in patients with polycystic ovary syndrome than in those with unexplained infertility. (PubMed)

Lower prevalence of non-cavity-distorting uterine fibroids in patients with polycystic ovary syndrome than in those with unexplained infertility. To study whether there is a difference in the prevalence of non-cavity-distorting uterine fibroids between infertile patients with polycystic ovary syndrome (PCOS) and those with unexplained infertility (UI).A secondary analysis of data from three randomized clinical trials.Academic health centers.A total of 2,249 patients with normal uterine (...) -distorting uterine fibroids was lower in women with PCOS than in those with UI (6.7% vs. 12.4%); this result held after patients were divided into Black and non-Black or into three different body mass index groups. After adjustment for all the other variables in the final model, patients with PCOS had a significantly lower prevalence of fibroids than those with UI (odds ratio 0.54). No differences in the prevalence of non-cavity-distorting fibroids with any dimensions ≥4 cm or the volume of the largest

2019 Fertility and Sterility Controlled trial quality: uncertain

45. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials. (PubMed)

Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials. Can asoprisnil, a selective progesterone receptor modulator, provide clinically meaningful improvements in heavy menstrual bleeding (HMB) associated with uterine fibroids with an acceptable safety profile?Uninterrupted treatment with asoprisnil for 12 months effectively controlled HMB (...) and reduced fibroid and uterine volume with few adverse events.In a 3-month study, asoprisnil (5, 10 and 25 mg) suppressed uterine bleeding, reduced fibroid and uterine volume, and improved hematological parameters in a dose-dependent manner.In two Phase 3, double-blind, randomized, placebo-controlled, multicentre studies, women received oral asoprisnil 10 mg, asoprisnil 25 mg or placebo (2:2:1) once daily for up to 12 months.Premenopausal women ≥18 years of age in North America with HMB associated

Full Text available with Trip Pro

2019 Human Reproduction Controlled trial quality: predicted high

46. Myometrial progesterone hyper-responsiveness associated with increased risk of human uterine fibroids. (PubMed)

Myometrial progesterone hyper-responsiveness associated with increased risk of human uterine fibroids. Uterine Fibroids (UFs) growth is ovarian steroid-dependent. Previous studies have shown that estrogen and progesterone play an important role in UF development. However, the mechanism underlying progesterone induced UF pathogenesis is largely unknown. In this study, we determined the expression of progesterone receptor and compared the expression level of progesterone-regulated genes (PRGs

2019 BMC Women's Health

47. Randomised trial of two embolic agents for uterine artery embolisation for fibroids: Gelfoam versus Embospheres (RAGE trial). (PubMed)

Randomised trial of two embolic agents for uterine artery embolisation for fibroids: Gelfoam versus Embospheres (RAGE trial). Uterine artery embolisation (UAE) is an established treatment option for women with symptomatic uterine fibroids who wish to avoid surgery. However the most efficacious embolic agent remains uncertain.We conducted a pilot double blind randomized controlled trial comparing Gelfoam with Embospheres in women undergoing UAE. Outcomes recorded at baseline, 24-h, 1 and 6 (...)  ± 26 in the E and G groups respectively. UFS-Qol HRQL also improved in both groups at 6 months, mean 41 ± 28 to 79 ± 20 and 53 ± 19 to 78 ± 21 in the E and G groups respectively.Uterine volume at 6 months reduced from 1018 ± 666mls to 622 ± 436 (p = 0.001) and from 1026 ± 756 to 908 ± 720 (p = 0.15) in the E and G groups respectively. There was a significant difference between groups for this parameter p = 0.01. All uterine arteries were patent at 24-h and 6 months. Complete (100%) fibroid

Full Text available with Trip Pro

2019 CVIR endovascular Controlled trial quality: predicted high

48. Application of oxytocin in ultrasound-guided percutaneous microwave ablation for treatment of hypervascular uterine fibroids: a preliminary report. (PubMed)

Application of oxytocin in ultrasound-guided percutaneous microwave ablation for treatment of hypervascular uterine fibroids: a preliminary report. Objective: This study evaluated the effect of oxytocin administration prior to microwave ablation (MWA) of hypervascular uterine fibroids. Methods: Thirty-two patients with 38 hypervascular uterine fibroids (Adler blood flow grade 3) were equally apportioned to receive intravenous oxytocin infusion (0.32 U/min) 20 min before ultrasound-guided (...) was noted. Conclusion: Intravenous oxytocin administered before percutaneous MWA of hypervascular uterine fibroids can effectively block the blood supply vessels of the myoma, reduce the heat sink effect, and thereby increase the ablation volume and improve the local therapeutic effect.

2019 International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group Controlled trial quality: uncertain

49. A comparative study on the effects of MRI- and CT-guided interventional therapies on uterine fibroids. (PubMed)

A comparative study on the effects of MRI- and CT-guided interventional therapies on uterine fibroids. To compare the effects of MRI- and CT-guided interventional therapies on uterine fibroids.A total of 280 patients with uterine fibroids who were treated in our hospital from August 2008 to February 2014 were selected and divided into a treatment group and a control group by random draw (n=140). The control group and the treatment group were subjected to CT- and MRI-guided interventional (...) therapies for uterine artery embolization.After three months of treatment, 94.3% and 92.9% of heavy menstrual bleeding and pelvic pressure of the treatment group were relieved respectively, which were similar to those of the control group (92.9% and 92.1% respectively) (P>0.05). The two groups had similar uterine and fibroid sizes before treatment, which were all significantly decreased after treatment (P<0.05) when the treatment group had significantly smaller uteri and fibroids than the control group

2019 Pakistan Journal Of Medical Sciences Controlled trial quality: uncertain

50. Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids

Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids 1 Translation of the executive summary of the assessment of potential Magnetresonanztomografie-gesteuerte hochfokussierte Ultraschalltherapie zur Behandlung des Uterusmyoms (Version 1.0; Status: 28 May 2014). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Executive (...) Summary IQWiG Reports – Commission No. E14-04 Magnetic resonance imaging-guided high-intensity focused ultrasound therapy for uterine fibroids 1 Executive summary of assessment of potential E14-04 Version 1.0 High-intensity focused ultrasound therapy for uterine fibroids 28 May 2014 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Magnetic resonance imaging-guided high-intensity focused ultrasound

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

51. Ultrasound-guided high-intensity focused ultrasound for uterine fibroids ? Assessment according to §137h Social Code Book V

Ultrasound-guided high-intensity focused ultrasound for uterine fibroids ? Assessment according to §137h Social Code Book V 1 Translation of the executive summary of the assessment according to § 137h Social Code Book (SGB) V Sonografiegesteuerte hochfokussierte Ultraschalltherapie beim Leiomyom des Uterus (Version 1.0; Status: 30 January 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely (...) authoritative and legally binding. Executive Summary IQWiG Reports – Commission No. H16-02B Ultrasound-guided high- intensity focused ultrasound therapy for uterine fibroids 1 Executive summary of assessment H16-02B according to §137h SGB V Version 1.0 USgHIFU for uterine fibroids 30 January 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ultrasound-guided high-intensity focused ultrasound

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

52. SonataT System for the removal of uterine fibroids

SonataT System for the removal of uterine fibroids Sonata™ System for the removal of uterine fibroids Sonata™ System for the removal of uterine fibroids NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Sonata™ System for the removal of uterine fibroids. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review (...) . 2015 Authors' objectives The Sonata™ System (previously VizAblate®), developed by Gynesonics, is an incisionless, transcervical system that combines ultrasound image guidance with radiofrequency (RF) ablation. The system is designed to treat symptomatic uterine fibroids in a hospital outpatient setting, depending on anaesthetic requirements. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Female; Humans; Leiomyoma; Uterine Neoplasms Language Published English Country

2015 Health Technology Assessment (HTA) Database.

53. Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: An Economic Analysis

Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: An Economic Analysis Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: An Economic Analysis Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: An Economic Analysis Babashov D, Palimaka S, Blackhouse G, O'Reilly D Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Babashov D, Palimaka S, Blackhouse G, O'Reilly D. Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: An Economic Analysis. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series; (15(5). 2015 Authors' conclusions Our findings suggest

2015 Health Technology Assessment (HTA) Database.

54. Magnetic Resonance?Guided High-Intensity Focused Ultrasound (MRgHIFU) Treatment of Symptomatic Uterine Fibroids: An Evidence-Based Analysis

Magnetic Resonance?Guided High-Intensity Focused Ultrasound (MRgHIFU) Treatment of Symptomatic Uterine Fibroids: An Evidence-Based Analysis Magnetic Resonance–Guided High-Intensity Focused Ultrasound (MRgHIFU) Treatment of Symptomatic Uterine Fibroids: An Evidence-Based Analysis Magnetic Resonance–Guided High-Intensity Focused Ultrasound (MRgHIFU) Treatment of Symptomatic Uterine Fibroids: An Evidence-Based Analysis Pron G Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pron G. Magnetic Resonance–Guided High-Intensity Focused Ultrasound (MRgHIFU) Treatment of Symptomatic Uterine Fibroids: An Evidence-Based Analysis. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series; 15(4). 2015 Authors' conclusions For women failing medical therapy and seeking alternatives to hysterectomy for symptomatic uterine

2015 Health Technology Assessment (HTA) Database.

55. Magnetic Resonance?Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: OHTAC Recommendation

Magnetic Resonance?Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: OHTAC Recommendation Magnetic Resonance–Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: OHTAC Recommendation Magnetic Resonance–Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: OHTAC Recommendation Ontario Health Technology Advisory Committee (OHTAC) Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ontario Health Technology Advisory Committee (OHTAC). Magnetic Resonance–Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: OHTAC Recommendation. Toronto: Health Quality Ontario (HQO). OHTAC Recommendation. 2015 Authors' conclusions Based on the current available evidence, OHTAC

2015 Health Technology Assessment (HTA) Database.

56. Frequency of uterine sarcomas in patients admitted for uterine fibroid surgery (PubMed)

Frequency of uterine sarcomas in patients admitted for uterine fibroid surgery To estimate the frequency of unsuspected uterine sarcoma identified postoperatively in women undergoing surgery for presumed benign uterine fibroids at a single university hospital.This was a retrospective single-center study; the records of all 2275 patients with uterine fibroids and uterine sarcomas from 2003 to 2015 were reviewed. Descriptive statistics were used to analyze demographic and clinical characteristics (...) . To calculate confidence intervals (CIs), the Clopper-Pearson Exact method was applied.Preoperatively, 2269 patients had presumed benign uterine fibroids, and six patients had suspected uterine sarcoma. Among the 2269 patients who underwent surgery for presumed uterine fibroids, endometrial stromal sarcoma was histopathologically revealed in only one patient [0.044%, 95% CI: (0.001-0.25)] after laparoscopic subtotal hysterectomy with morcellation. All six patients who were preoperatively diagnosed having

Full Text available with Trip Pro

2017 Journal of the Turkish German Gynecological Association

57. Aromatase inhibitors for uterine fibroids. (PubMed)

Aromatase inhibitors for uterine fibroids. Uterine fibroids, also called uterine leiomyomas or myomas, are the most common benign tumours in women of reproductive age. Albeit generally benign, uterine fi broids can have a major impact on women's health and quality of life by contributing to abnormal uterine bleeding and causing pelvic pressure symptoms (such as increased urinary frequency, pelvic pain and constipation). Traditional treatments for symptomatic fi broids include a variety (...) trial did not report data on fibroid volume in a form that permitted calcuation of an odds ratio. Morevoer it was unblinded and included only 60/70 women in analysis.Evidence is insufficient to support the use of AI drugs in the treatment of women with uterine fibroids.

2013 Cochrane

58. Magnetic Resonance-guided Focused Ultrasound (MRgFUS) therapy (ExAblate InSightec Ltd.) for ablation of uterine fibroids

Magnetic Resonance-guided Focused Ultrasound (MRgFUS) therapy (ExAblate InSightec Ltd.) for ablation of uterine fibroids Magnetic Resonance-guided Focused Ultrasound (MRgFUS) therapy (ExAblate; InSightec Ltd.) for ablation of uterine fibroids Magnetic Resonance-guided Focused Ultrasound (MRgFUS) therapy (ExAblate; InSightec Ltd.) for ablation of uterine fibroids Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Magnetic Resonance-guided Focused Ultrasound (MRgFUS) therapy (ExAblate; InSightec Ltd.) for ablation of uterine fibroids. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2014 Authors' conclusions Uterine fibroids (also called leiomyomata or myomas) are benign tumors of the myometrium, the smooth muscle layer of the uterus. Most women develop fibroids. In the sixth decade of life, the prevalence of fibroids is almost 70% in Caucasian

2014 Health Technology Assessment (HTA) Database.

59. Laparoscopic radiofrequency volumetric thermal ablation (Acessa System Halt Medical Inc.) for treatment of uterine fibroids

Laparoscopic radiofrequency volumetric thermal ablation (Acessa System Halt Medical Inc.) for treatment of uterine fibroids Laparoscopic radiofrequency volumetric thermal ablation (Acessa System; Halt Medical Inc.) for treatment of uterine fibroids Laparoscopic radiofrequency volumetric thermal ablation (Acessa System; Halt Medical Inc.) for treatment of uterine fibroids Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Laparoscopic radiofrequency volumetric thermal ablation (Acessa System; Halt Medical Inc.) for treatment of uterine fibroids. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2014 Authors' conclusions Uterine fibroids (also called leiomyomata or myomas) are benign tumors of the myometrium, the smooth muscle layer of the uterus. In the sixth decade of life, the prevalence of fibroids is almost 70% in Caucasian women and 80% in black

2014 Health Technology Assessment (HTA) Database.

60. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids

Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation CADTH. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that ulipristal acetate be listed for the treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age, who are eligible for surgery, if the following

2014 Health Technology Assessment (HTA) Database.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>